In Brief: FDA Reproductive Health Drugs Advisory Committee
Executive Summary
FDA Reproductive Health Drugs Advisory Committee: Postcoital emergency use of "certain" oral contraceptives will be discussed by committee (formerly the Fertility & Maternal Health Drugs Advisory Committee) June 28. FDA received a citizen's petition from the Center for Reproductive Law & Policy in November 1994 requesting inclusion of the use in OC labeling. FDA denied the petition but "determined that it would be appropriate to discuss the scientific issues related to the safety and effectiveness of this use." The meeting will begin at 9 a.m. at the Holiday Inn, Gaithersburg, Md...
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth